Cryptobiotix provides an ex vivo SIFR® technology platform that simulates the full human gastrointestinal tract—including digestion, colonic fermentation, and host–microbiome interactions—under biorelevant conditions. The automated, modular system delivers high‑throughput, mechanistic data on dose‑response, mode of action, and inter‑individual variability, supporting de‑risking, regulatory submissions, and IP protection for food, pharma, biotech, and animal‑health product development.
Funding
Funding not disclosed
Founders
Product
Problem
Preclinical assessment of how ingested compounds interact with digestion, the gut microbiome, and the host is limited by in vivo complexity and a lack of predictive, high‑throughput models, leading to uncertainty in efficacy, safety, and clinical translation.
Solution
Cryptobiotix offers the ex vivo SIFR® technology pipeline, an automated, modular platform that simulates the entire human gastrointestinal tract—including digestion, colonic fermentation, and host–microbiome interactions—under biorelevant conditions. The system preserves the individuality of donor microbiota, enabling the study of inter‑individual variability and responder versus non‑responder profiles. By delivering mechanistic, dose‑response, and mode‑of‑action data that have been validated to predict clinical outcomes, SIFR® supports de‑risking of product development, informs regulatory dossiers, and guides IP protection. Results are provided in comprehensive, visual reports that translate complex microbiome and metabolite data into actionable insights for decision‑making.
Target Audience
Primary customers are food and nutrition companies, pharmaceutical and biotech developers, and animal‑health firms seeking preclinical data on functional ingredients, probiotics, postbiotics, drugs, or feed additives.
Features
- Automated ex vivo simulation of full GI digestion, colonic fermentation, and host epithelial‑immune response
- Modular design allowing independent or combined assessment of digestion, microbiome fermentation, or host interaction
- High‑throughput processing of multiple donor microbiota to capture inter‑individual variability and responder profiling
- Validated predictive capability for clinical shifts in microbiome composition, metabolite production, and health outcomes
- Biorelevant physiological conditions preserving both luminal and mucosal microbiome communities
- Actionable reporting with detailed visualizations, dose‑response curves, and mechanistic insights
- Optional biobanking of donor samples to tailor cohort selection and accelerate study timelines